On Thursday, Shares of Wells Fargo & Company (NYSE:WFC), gained 0.71% to $52.56.
Zac Brown Band, Wells Fargo and inMarket have teamed up to support Warriors to Summits — part of No Barriers USA, a nonprofit that empowers veterans, transitioning service members with disabilities and their families — by deploying the world’s first beacon engagement program for a major recording artist during its 9/11 show at Wrigley Field in Chicago.
Attendees at Zac Brown Band’s concert at Wrigley Field who have the Zac Brown Band Live App (or others in the inMarket network) will be part of the experience. The proximity engagement will promote the Warriors to Summits pledge, asking folks to respect, support and honor our veterans.
Through its partnership with inMarket, Zac Brown Band becomes the first major recording artist to leverage beacons at scale. inMarket, which reaches 36MM monthly active app users per month, is the world’s largest beacon proximity platform.
Wells Fargo & Company provides retail, commercial, and corporate banking services to individuals, businesses, and institutions. Its Community Banking segment offers checking, savings, market rate, individual retirement, and health savings accounts, in addition to time deposits and remittances; and lines of credit, auto floor plan lines, equity lines and loans, equipment and transportation loans, education and residential mortgage loans, and debit and credit cards.
Shares of Cytori Therapeutics, Inc. (NASDAQ:CYTX), surged 16.23% to $0.48, during its last trading session.
Cytori Therapeutics, declared the publication recently of the results from the 12 month clinical follow up of patients enrolled in the Scleradec-I clinical trial from hand dysfunction common in patients with the rare disease scleroderma. The Scleradec-I trial, an investigator-initiated, open-label 12 patient trial, was led by Dr. Brigitte Granel and Dr. Guy Magalon from the Assistance Publique des Hôpitaux de Marseille.
The publication documented that a single treatment with Cytori Cell Therapy™, known as ECCS-50, offered prolonged improvements in patients with impaired hand function due to scleroderma. Specifically, hand function assessed using the validated clinical measure known as the Cochin Hand Function Scale and overall health status using the Scleroderma Health Activity Questionnaire improved from baseline by an average of 51.3% and 46.8%, respectively, at 12 months (p≤0.001 for both). Raynaud’s Condition Score, which measures the incidence and severity of Raynaud’s phenomena, was reduced by 63.2% from baseline at 12 months (p<0.001). Other key findings comprise a 30.5% improvement from baseline in grip strength (p=0.002) and 34.5% improvement from baseline in pain (p=0.052).
Relative to the data measured in these patients at 6 months after treatment, the 12 month data comprised evidence of on-going benefit across a number of endpoints. For example, fibrosis of the hand, an important pathophysiologic feature of the disease, was assessed using the modified Rodnan Skin Score and declined by 22.9% relative to baseline (p=0.014). Similarly, capillaroscopic assessment of vascular suppression improved by 35% contrast to baseline (p≤0.001).
Cytori Therapeutics, Inc., a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy comprising of a heterogeneous population of specialized cells, counting stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury.
Finally, Noble Energy, Inc. (NYSE:NBL), ended its last trade with 1.85% gain, and closed at $30.75.
Noble Energy, offered new third quarter 2015 sales volume guidance, with the midpoint of the Company’s new expectation representing a 10 thousand barrel of oil equivalent per day (MBoe/d) improvement over the midpoint of its prior estimate. Following strong volume performance in July and August, the Company has raised its anticipated third quarter 2015 sales volume range to between 360 and 370 MBoe/d. The improvement was driven primarily by improved well performance and infrastructure expansion in the DJ Basin. In addition, strong production is resulting from the Company’s assets in Texas (Eagle Ford and Delaware), Marcellus Shale, Israel, and Equatorial Guinea. Natural gas sales in Israel set a record in August as the Company’s Tamar asset averaged more than one billion cubic feet of natural gas per day, gross, for the month.
The third-party Lucerne-2 plant has been tested to a nameplate capacity of 200 million cubic feet of natural gas per day (MMcf/d). Addition of the Lucerne-2 plant has expanded total system natural gas processing capacity to 840 MMcf/d, resulting in line pressures being reduced by between 50 and 100 psi in various parts of Greater Wattenberg while also providing additional capacity for future growth. Noble Energy’s net DJ Basin production has averaged about 115 MBoe/d through the first two months of the third quarter of 2015.
Noble Energy, Inc., an independent energy company, engages in the acquisition, exploration, and production of crude oil, natural gas, and natural gas liquids worldwide. Its principal projects are located in onshore DJ Basin and Marcellus Shale, the United States; the deepwater Gulf of Mexico; offshore West Africa; and offshore Eastern Mediterranean.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
